GlassScriptPhysician profile
Marco Bonilla
NPI 1932636636
$148,164.08
in general payments reported to CMS, 2019-2025
15 companies · $88K in 2025
The $88K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $118 · 2023: $11K · 2024: $50K · 2025: $88K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $66K · Consulting Fee: $27K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $24K · Travel and Lodging: $22K · Food and Beverage: $9,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,657.50 |
| Consulting Fee | $26,892.47 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $23,907.00 |
| Travel and Lodging | $22,474.52 |
| Food and Beverage | $9,114.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $69,411.05 | 2023-2025 | Tavneos, Uplizna |
| Travere Therapeutics, INC. | $59,342.83 | 2023-2025 | Filspari |
| Apellis Pharmaceuticals, INC. | $9,790.50 | 2025 | Empaveli |
| Vertex Pharmaceuticals Incorporated | $5,625.29 | 2025 | |
| Calliditas Therapeutics US INC. | $2,722.12 | 2024-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $299.64 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $246.45 | 2023-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $226.05 | 2022-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $116.18 | 2023 | Benlysta |
| Lilly USA, LLC | $112.28 | 2024 | Jardiance |
| Kyowa Kirin, INC. | $80.52 | 2025 | |
| Genentech, INC. | $68.21 | 2025 | Gazyva |
| Otsuka America Pharmaceutical, INC. | $52.49 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $50.00 | 2025 | |
| Veloxis Pharmaceuticals, INC. | $20.47 | 2025 | Envarsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marco Bonilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.